SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #1
Under the Securities Exchange Act of 1934
TRANSKARYOTIC THERAPIES, INC.
----------------------------
(Name of Issuer)
Common Stock par value $.01 per share
---------------------------------------------------------------------------
(Title of Class of Securities)
893735 10 0
-----------------
(CUSIP Number)
Edward H. Stratemeier, Esq.
General Counsel
Aventis Pharmaceuticals
Route 202-206, P. O. Box 6800
Bridgewater, NJ 08807-0800
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 15, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1(e), 13d-1(f), or 13d-1(g), check the following
box. [ ]
Page 1 of 12
Exhibit Index is at Pages 6 and 7
<PAGE> 2
CUSIP No. 893735 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Aventis Pharmaceuticals Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds WC
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 2,187,408
Number of _____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by _____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 2,187,408
Person With _____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 2,187,408
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 9.6%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 3
CUSIP No. 893735 10 0
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 2,187,408
Number of _______________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by _______________________________________________________________
Each
Reporting 9) Sole Dispositive Power 2,187,408
Person With _______________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 2,187,408
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 9.6%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 4
CUSIP No. 893735 10 0
This Amendment no. 1 to the Statement on Schedule 13D (the Schedule
13D) with respect to the Common Stock of Transkaryotic Therapies, Inc.
(the Issuer), of Aventis Pharmaceuticals Inc., a Delaware corporation (API),
and HMR Pharma, Inc., a Delaware corporation (HMR Pharma), is filed solely
to incorporate the following exhibits:
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Exhibit 99.1 Information concerning directors and executive officers of
Aventis Pharmaceuticals Inc. and HMR Pharma, Inc.
Exhibit 99.2 Information concerning members of Supervisory Board,
Management Board and Executive Committee of Aventis S.A.
<PAGE> 5
CUSIP No. 893735 10 0
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
AVENTIS PHARMACEUTICALS INC.
Date: July 18, 2000 By: /s/ Rebecca R. Tilden
Rebecca R. Tilden
Vice President and Secretary
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
HMR PHARMA, INC.
Date: July 18, 2000 By: /s/ Joan A. Hanlon
Joan A. Hanlon
Vice President and Treasurer
<PAGE> 6
CUSIP No. 893735 10 0
EXHIBIT INDEX
Exhibit No. Description Page No.
----------- ------------ ---------
99.1 Information concerning directors and 8
executive officers of API and HMR Pharma.
99.2 Information concerning members of the Supervisory 11
Board, Board of Management and Executive Committee
of Aventis S.A.
99.3 Agreement to File Jointly dated December 22,
1999, by and between API and HMR Pharma
(incorporated by reference from Schedule 13D dated
December 22, 1999).
99.4 Class D Preferred Stock Purchase Agreement,
dated May 18, 1994, by and between the Issuer
and API (incorporated by reference from
Exhibit 10.6 to Amendment No. 5 to the
Registration Statement on Form S-1 of the
Issuer filed with the Securities and Exchange
Commission (the "Commission") on October 15,
1996 (the "Registration Statement")).
99.5 Class E Preferred Stock Purchase Agreement,
dated March 1, 1995, by and between the Issuer
and API (incorporated by reference from
Exhibit 10.7 to Amendment No. 5 to the
Registration Statement).
99.6 Class F Preferred Stock Purchase Agreement,
dated October 26, 1995, by and among the
Issuer and certain Purchasers named therein
(incorporated by reference from Exhibit 10.8
to Amendment No. 5 to the Registration
Statement).
99.7 Amended and Restated License Agreement, dated
March 1, 1995, by and between API and the
Issuer (incorporated by reference from
Exhibit 10.33 to Amendment No. 5 to the
Registration Statement).
99.8 License Agreement, dated March 1, 1995, by
and between API and the Issuer (incorporated
by reference from Exhibit 10.34 to Amendment
No. 5 to the Registration Statement).
99.9 Amended and Restated Registration Rights
Agreement, dated November 3, 1993 and amended
on May 13, 1994, March 1, 1995, October 26,
1995, July 10, 1996 and August 7, 1996, by
and among the Issuer and certain holders of
the Issuer's Preferred Stock named therein
(incorporated by reference from Exhibit 10.11
<PAGE> 7
CUSIP No. 893735 10 0
to Amendment No. 5 to the Registration
Statement).
99.10 Fifth Amendment to Registration Rights
Agreement dated October 1, 1996 by and among
the Issuer and certain holders of the
Issuer's Preferred Stock named therein
(incorporated by reference from Exhibit 10.36
to Amendment No. 5 to the Registration
Statement).
<PAGE> 8
CUSIP No. 893735 10 0
Exhibit 99.1
Directors and Officers of Aventis Pharmaceuticals Inc. and
HMR Pharma, Inc.
The following sets forth the name, title, business address, and
present principal occupation of each of the directors and executive officers
of API as of June 5, 2000. All are citizens of the United States unless
otherwise indicated in parentheses under his or her name.
AVENTIS PHARMACEUTICALS INC.
<TABLE>
<CAPTION>
<S> <C> >C>
Name Title Address
Daniel Camus Chief Financial Officer Aventis Pharma AG
(Germany) of Aventis Pharma AG 65926 Frankfurt Main
and Director of API Germany
Frank L. Douglas, Ph.D., M.D. Head of Research and Aventis Pharma AG
Development of Aventis 65926 Frankfurt Main
Pharma AG and Director Germany
of API
Richard J. Markham Chief Executive Officer Route 202-206
of Aventis Pharma AG Bridgewater, NJ 08807-0800
and Director of API
Thierry Soursac, M.D., Ph.D. Head of Commercial Route 202-206
Operations for Aventis Bridgewater, NJ 08807-0800
Pharma AG and Director
of API
Gerald P. Belle President and Chief Executive Route 202-206
Officer and Director of API Bridgewater, NJ 08807-0800
Harold F. Boardman Senior Vice President, Legal Route 202-206
Bridgewater, NJ 08807-0800
Susan Ketterman Vice President, Head of NA Route 202-206
Human Resources Bridgewater, NJ 08807-0800
John R. Leone Sr. Vice President, US Route 202-206
Commercial Operations Bridgewater, NJ 08807-0800
Jurgen Lasowski Vice President, Business Route 202-206
Development and Strategy, Bridgewater, NJ 08807-0800
NA
Philippe M. Maitre Vice President, Head of NA Route 202-206
(France) Finance and Information Systems Bridgewater, NJ 08807-0800
and Chief Financial Officer
Daniel G. Maher Vice President, Head of NA 10236 Marion Park Drive
Industrial Operations Kansas City, MO 64137
Francois Nader, MD Vice President, Head of NA Route 202-206
Medical Affairs/Regulatory Bridgewater, NJ 08807-0800
<PAGE> 9
CUSIP No. 893735 10 0
Charles F. Rouse, III Vice President, Head of NA Route 202-206
Communications and Bridgewater, NJ 08807-0800
Community Affairs
Mark R. Shaw Vice President, Head of NA Route 202-206
Administrative Services Bridgewater, NJ 08807-0800
Edward H. Stratemeier Vice President, Head of NA Route 202-206
Legal, Government Affairs Bridgewater, NJ 08807-0800
and Policy
Robert J. Carmody Vice President, North America Route 202-206
Tax Bridgewater, NJ 08807-0800
Gerald Dahling Senior Vice President, 2, Avenue Pont Pasteur
Global Patents Lyon, France 69007
Charles D. Dalton Vice President and Assistant Route 202-206
Secretary Bridgewater, NJ 08807-0800
Tim C. Gau Senior Vice President, Route 202-206
Head of Global Drug Product Bridgewater, NJ 08807-0800
Realization, Drug Regulatory
Affairs & Drug Surveilance
Thomas Hofstaetter Senior Vice President, Route 202-206
Corporate Development Bridgewater, NJ 08807-0800
Claude Ourceyre Vice President, Corporate Route 202-206
Human Resources - Bridgewater, NJ 08807-0800
Bridgewater Center
Kirk Schueler Senior Vice President, Global Route 202-206
Marketing Bridgewater, NJ 08807-0800
Errol de Souza Vice President, Head of Route 202-206
DI&A U.S. Bridgewater, NJ 08807-0800
Scott F. Stevens Vice President, Global Tax Route 202-206
Bridgewater, NJ 08807-0800
Rebecca R. Tilden Vice President and Secretary 10236 Marion Park Drive
Kansas City, MO 64137
Michael A. Yeomans Vice President, Licensing & Route 202-206
Alliances Bridgewater, NJ 08807-0800
Terry G. King Treasurer Route 202-206
Bridgewater, NJ 08807-0800
E. Todd Johnson Assistant Treasurer 10236 Marion Park Drive
Kansas City, MO 64137
Owen K. Ball, Jr. Assistant Secretary Route 202-206
Bridgewater, NJ 08807-0800
Christian Gelain Assistant Secretary 25, Quai Paul Doumer
(France) Courbevoie, France 92408
Ross J. Oehler Assistant Secretary Route 202-206
Bridgewater, NJ 08807-0800
Robert J. Werner Assistant Secretary Route 202-206
Bridgewater, NJ 08807-0800
</TABLE>
<PAGE> 10
CUSIP No. 893735 10 0
<TABLE>
<CAPTION>
HMR PHARMA, INC.
<S> <C> >C>
Directors:
Gerald P. Belle Chairman Route 202-206
Bridgewater, NJ 08807-0800
Philippe M. Maitre Director Route 202-206
(France) Bridgewater, NJ 08807-0800
Edward H. Stratemeier Director Route 202-206
Bridgewater, NJ 08807-0800
Officers:
Phillip R. Ridolfi President 3711 Kennett Pike, Suite 200
Greenville, DE 19807
Joan A. Hanlon Vice President & Treasurer 3711 Kennett Pike, Suite 200
Greenville, DE 19807
Andrea Q. Ryan Secretary 3711 Kennett Pike, Suite 200
Greenville, DE 19807
</TABLE>
<PAGE> 11
CUSIP No. 893735 10 0
Exhibit 99.2
Certain Information Relating to Directors and Executive Officers
Supervisory Board, Board of Management and Executive Committee of Aventis SA
<TABLE>
<CAPTION>
Name and Business Address Principal Present Occupation
SUPERVISORY BOARD
<S> <C>
Marc Vienot Chairman of the Supervisory Board of Aventis
(France)
Dr. Martin Fruhauf Vice-Chairman of the Supervisory Board of Aventis
(Germany)
Jean-Marc Bruel Member of the Supervisory Board of Aventis
(France)
Serge Kampf Member of the Supervisory Board of Aventis
(France)
Prof. Dr. Drs. h. c. Hubert Markl Member of the Supervisory Board of Aventis
(Germany)
Dr. Gunter Metz Member of the Supervisory Board of Aventis
(Germany)
Didier Pineau-Valencienne Member of the Supervisory Board of Aventis
(France)
Seham Razzouqi Member of the Supervisory Board of Aventis
(Kuwait)
Michel Renault Member of the Supervisory Board of Aventis
(France)
Dr. Hans-Jurgen Schinzler Member of the Supervisory Board of Aventis
(Germany)
BOARD OF MANAGEMENT
Jurgen Dormann Chairman of the Board of Management of Aventis
(Germany)
Jean-Rene Fourtou Vice-Chairman of the Board of Management of Aventis
(France)
<PAGE> 12
CUSIP No. 893735 10 0
Igor Landau Member of the Board of Management of Aventis
(France)
Horst Waesche Member of the Board of Management of Aventis
(Germany)
EXECUTIVE COMMITTEE
Jurgen Dormann Chairman of the Board of Management of Aventis
(Germany)
Jean- Rene Fourtou Vice-Chairman of the Board of Management of Aventis
(France)
Alain Godard Chief Executive Officer of Aventis Agriculture
(France)
Igor Landau Member of the Board of Management of Aventis
(France)
Patrick Langlois Group Executive Vice President - Chief Financial
(France) Officer
Richard J. Markham Chief Executive Officer of Aventis Pharma
(United States)
Rene Penisson Group Executive Vice President - Human Resources
( France)
Horst Waesche Member of the Board of Management of Aventis
(Germany)
</TABLE>
